이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

다발성 경화증 임상시험을 위한 전통적 대 조기 공격적 요법 (TREAT-MS)

2026년 9월 22일 업데이트: Johns Hopkins University

다발성 경화증이 있는 사람에서 초기 공격적 요법 대 확대 요법의 중기 효과를 평가하기 위한 실용적인 시험

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.

The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

연구 개요

상세 설명

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.

The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.

Hypotheses/Objectives: The main hypothesis is that intermediate-term disability will be reduced by earlier use of higher-efficacy medications. Additional objectives include a) evaluating the magnitude of the treatment effect in patients deemed to be at higher risk versus lower risk of longer-term disability (we hypothesize that the effect size will be greater in the former group) and b) evaluating if, among those without indications of a high risk of longer-term disability, breakthrough disease can be successfully managed by switching to a different first-line therapy or if escalation is required at that time (we hypothesize that switching to a higher-efficacy therapy will be more effective in preventing disability in this group).

There is a great unmet need to identify the most appropriate treatment strategy for people with MS, especially early in the disease course when it may be possible to maximize an individual's chance for preventing long-term disability. There is a paucity of evidence-based guidelines to help clinicians, patients, and payers determine which treatment strategy is best for an individual with MS. Making treatment decisions is a daunting task, and the individualized benefit-risk assessment becomes increasingly difficult as new therapies emerge. Without the availability of direct comparative trials, clinicians and patients are forced to scrutinize observational studies that only provide basic insights into what may be the best treatment path moving forward. It is equally challenging to define what constitutes a suboptimal response to a DMT for an individual patient. Clinicians lack guidance on when to switch therapies and whether to consider a different first-line or if clinicians should escalate immediately to higher-efficacy therapies, so further consensus is needed to determine the optimal time to switch therapies and escalate therapy if an individual is on a first-line therapy from the start. The TREAT-MS trial will help inform patients and the broader health care community on whether patients would most benefit from early, possibly more risky aggressive therapy or if starting with a less aggressive (and, often, less risky) therapy, followed by a switch if breakthrough disease occurs, is warranted. In addition, this study may help identify specific patient populations and/or short-term clinical and paraclinical biomarkers that are strongly predictive of long-term disability that can ensue from MS.

Accrual of sustained disability is the most feared complication for people with MS, and the patient's own perception of their well-being or ill-being has a profound impact on their quality of life. The heterogeneity and unpredictability of MS, along with lack of agreed upon treatment guidelines, augments this fear, leading to a significant negative impact on quality of life. Even patients who are deemed to have "mild" MS experience a significant negative impact on their health-related quality of life that is similar in magnitude to what patients with other severe chronic conditions (i.e., congestive heart failure and chronic obstructive pulmonary disease) report. An extremely important goal for any intervention is to help improve or maintain a high quality of life; therefore, in addition to classic clinical endpoints (e.g. slowing disability progression), the TREAT-MS trial will capture several important and meaningful PROs that will shed light on what treatment strategies may be the best from a patient-centered perspective.

COVID-19 Related Substudy:

Since early 2020, the coronavirus disease 2019 (COVID-19) pandemic has caused clinical care and research disruptions nationwide, including for patients enrolled in the TREAT-MS trial. Many patients with MS, as well as their clinicians, are fearful that MS or the MS therapy they are using may increase the risk or severity of COVID-19 infection. Whether a person with early MS is more likely to experience more severe COVID-19 if treated with a higher-efficacy therapy is not known. Further, whether COVID-19-induced disruptions in therapy or other clinical care increase MS disease activity or MS symptoms is not clear but is relevant, particularly since greater MS activity in the early therapeutic course is associated in observational studies with worse long-term outcomes. Moreover, it is unclear if pre-pandemic anxiety and depression, common comorbidities in people with MS, contribute to decisions to delay care, overall or differently depending on therapeutic strategy (higher-efficacy vs. traditional). TREAT-MS provides an optimal cohort in which to investigate the effect of the COVID-19 pandemic on MS outcomes.

COVID-19 Substudy Aim 1. To evaluate if patients enrolled in TREAT-MS delayed or altered their disease-modifying therapy schedule or other MS care, and whether such alterations are associated with a greater degree of breakthrough inflammatory disease activity or the development of new (or worsening baseline) MS symptoms.

COVID-19 Substudy Aim 2: To evaluate if patients with MS treated with higher-efficacy, versus traditional, therapies differ in the risk of severe COVID-19 infection, defined as requiring hospitalization (with or without intubation) or mortality due to COVID-19.

연구 유형

중재적

등록 (실제)

900

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • University of Alabama at Birmingham
      • Mobile, Alabama, 미국, 36604
        • The University of South Alabama
    • Arizona
      • Phoenix, Arizona, 미국, 85013
        • St. Joseph's Hospital & Medical Center - Barrow Neurological Institute
    • California
      • Carmichael, California, 미국, 95608
        • CommonSpirit Health Research Institute
      • Los Angeles, California, 미국, 90095
        • University of California, Los Angeles
      • Los Angeles, California, 미국, 90048
        • Cedars-Sinai Medical Center
      • San Diego, California, 미국, 92037
        • University of California, San Diego
      • San Francisco, California, 미국, 94158
        • University of California, San Francisco
    • Delaware
      • Newark, Delaware, 미국, 19713
        • Christiana Care Health Services, Inc.
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20007
        • Georgetown University
    • Florida
      • Gainesville, Florida, 미국, 32611
        • University of Florida
      • Miami, Florida, 미국, 33136
        • University of Miami
      • Tampa, Florida, 미국, 33612
        • University of South Florida Health
    • Illinois
      • Chicago, Illinois, 미국, 60612
        • Rush University Medical Center
    • Kansas
      • Kansas City, Kansas, 미국, 66160
        • The University of Kansas Medical Center (KUMC)
    • Kentucky
      • Louisville, Kentucky, 미국, 40207
        • Norton Neurology MS Services
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • The Johns Hopkins Hospital
      • Baltimore, Maryland, 미국, 21201
        • University of Maryland, Baltimore
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • Massachusetts General Hospital
      • Worcester, Massachusetts, 미국, 01655
        • University of Massachusetts Medical School
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • University of Michigan
      • Detroit, Michigan, 미국, 48201
        • Wayne State University
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Mayo Clinic
    • Montana
      • Billings, Montana, 미국, 59101
        • Billings Clinic
      • Great Falls, Montana, 미국, 59405
        • Advanced Neurology Specialists
    • Nebraska
      • Omaha, Nebraska, 미국, 68198
        • University of Nebraska Medical Center
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • Hackensack University Medical Center
    • New York
      • New York, New York, 미국, 10032
        • Columbia University Medical Center
      • New York, New York, 미국, 10016
        • New York University School of Medicine
      • New York, New York, 미국, 10029
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Cincinnati, Ohio, 미국, 45219
        • University of Cincinnati
      • Columbus, Ohio, 미국, 43214
        • OhioHealth Research Institute
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • Oklahoma Medical Research Foundation
    • Oregon
      • Portland, Oregon, 미국, 97225
        • Providence Health and Services - Oregon
    • Pennsylvania
      • Danville, Pennsylvania, 미국, 17822
        • Geisinger Clinic
      • Pittsburgh, Pennsylvania, 미국, 15212
        • Allegheny Health Network Research Institute
    • Tennessee
      • Nashville, Tennessee, 미국, 37215
        • Vanderbilt Comprehensive MS Center
    • Texas
      • Dallas, Texas, 미국, 75246
        • Baylor Scott and White Health
      • Dallas, Texas, 미국, 75390-8806
        • University of Texas Southwestern Medical Center
      • Round Rock, Texas, 미국, 78681
        • Central Texas Neurology Consultants
    • Utah
      • Salt Lake City, Utah, 미국, 84108
        • University of Utah
    • Vermont
      • Burlington, Vermont, 미국, 05405
        • The University of Vermont and State Agricultural College
    • Virginia
      • Christiansburg, Virginia, 미국, 24073
        • Blacksburg Neurology
      • Norfolk, Virginia, 미국, 23502
        • Neurology Consultants of Tidewater
    • Washington
      • Seattle, Washington, 미국, 98122
        • Swedish Health Services
      • Seattle, Washington, 미국, 98133
        • University of Washington
    • Wisconsin
      • Milwaukee, Wisconsin, 미국, 53226
        • Medical College of Wisconsin

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Aged 18-60 years
  • Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are not eligible]
  • Must be EITHER John Cunningham (JC) virus antibody negative or low positive (index antibody titer <0.9), OR negative for: Hepatitis B and C, tuberculosis
  • HIV negative
  • No chemotherapy in past year; if patient has prior history of chemotherapy or malignancy, documentation in chart explaining why potential risks of higher-efficacy therapy are justified

Exclusion Criteria:

  • Prior treatment with rituximab, ocrelizumab, ofatumumab, alemtuzumab, mitoxantrone or cladribine
  • Prior treatment with any other MS DMT for more than 6 months
  • Prior treatment with experimental aggressive therapies (e.g., T-cell vaccine, total lymphoid radiation, stem cells)
  • Treatment with teriflunomide within past 2 years (even for ≤ 6 months), unless rapid wash out done (i.e., with cholestyramine or activated charcoal)
  • Treatment in the past 6 months with any MS DMT
  • Prior treatment with any other investigational immune-modulating /suppressing drug for MS not listed above
  • Pregnant or breast-feeding
  • Women of child-bearing age who are planning or strongly considering conception during the study time frame

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Early Aggressive Therapy

Early Aggressive Therapy choices and maximum allowable doses:

  • Natalizumab/natalizumab-sztn (Tysabri/Tyruko), 300 mg IV q 4 wks
  • Alemtuzumab (Lemtrada), 12 mg IV daily (QD) for 5 days; 1 yr later: 12 mg IV QD for 3 days
  • Ocrelizumab (Ocrevus), 300 mg IV every 2 wks (for 2 doses) at initiation; 600 mg IV q 6 mths
  • Rituximab/rituximab biosimilars (Rituxan/Riabni/Truxima/Ruxience), 1000 mg IV every 2 wks (for 2 doses); may repeat q 16-24 wks
  • Cladribine (Mavenclad), 3.5 mg per kg body wt orally divided into 2 yrly tmt courses (1.75 mg per kg body wt each yr); yrly tmt course divided into 2 tmt cycles; administer cycle dose as 1-2 tablets QD over 4-5 days
  • Ofatumumab (Kesimpta), 20 mg SC wkly for wks 0, 1 and 2; 20 mg subcutaneously (SC) mthly starting at wk 4
  • Ublituximab-xiiy (Briumvi), 150 mg IV (1st dose); 450 mg IV 2 wks after first dose; 450 mg IV q 24 wks
  • Ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), 920 mg ocrelizumab and 23,000 U hyaluronidase SC q 6 months

Early Aggressive Therapy

다른 이름들:
  • Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo
활성 비교기: Traditional Therapy

Traditional Therapy choices and maximum allowable doses:

  • Glatiramer acetate (Copaxone, Glatopa, and other generics), 20 mg SC daily, or 40 mg SC 3 times a wk
  • Intramuscular (IM) interferon (Avonex), 30 mcg IM weekly
  • SC interferon (Betaseron, Extavia, Rebif), 0.25 mg SC every other day (Betaseron, Extavia); 44 mcg SC 3 times a wk (Rebif)
  • Pegylated interferon (Plegridy), 125 mcg SC every 14 days
  • Teriflunomide (Aubagio), 14 mg PO QD
  • Dimethyl fumarate (Tecfidera and generics), 240 mg PO twice a day (BID)
  • Diroximel fumarate (Vumerity), 462 mg PO BID
  • Monomethyl fumarate (Bafiertam), 190 mg PO BID
  • Fingolimod (Gilenya and generics), 0.5 mg PO QD
  • Siponimod (Mayzent), 1 mg PO QD or 2 mg PO QD
  • Ozanimod (Zeposia), 0.92 mg PO QD
  • Ponesimod (Ponvory), 20 mg PO QD
  • Fingolimod ODT (Tascenso), 0.25 mg PO QD if <=40 kg; 0.5 mg PO QD if > 40 kg

Traditional Therapy

다른 이름들:
  • 코팍손, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Time to sustained disability progression
기간: From date of randomization until the date of first documented sustained disability progression, up to 99 months

Time to sustained disability progression is measured by the Expanded Disability Status Scale plus (EDSS+): a composite endpoint that includes EDSS change (change at any 6 month time point of > or = 1.0 point if baseline EDSS is < or = 5.5 or of > or = 0.5 if baseline EDSS is > or = 6.0, that is sustained 6 months later) OR 20% worsening on either of two specific components of the Multiple Sclerosis Functional Composite (MSFC), the timed 25-foot walk test (T25FWT) and the nine hole peg test (9HPT) that is sustained 6 months later.

From date of randomization until the date of first documented sustained disability progression, up to 99 months
Change in Overall Burden of MS
기간: up to 48 weeks from enrollment into COVID-19 related substudy

The change in overall burden of MS will be defined for the COVID-19 related substudy as the occurrence of breakthrough disease (relapses or new MRI activity) or the development of new (or worsening baseline) MS symptoms, which are (for TREAT-MS) and will continue to be (during the substudy) documented at clinical visits, whether in-person or on tele-visits.

up to 48 weeks from enrollment into COVID-19 related substudy

2차 결과 측정

결과 측정
측정값 설명
기간
Patient-Determined Disease Steps (PDDS)
기간: up to 99 months

PDDS is a self-assessment scale of disability due to MS on a scale from 0 to 8 and will be administered as an electronic patient-reported outcome (PRO).

up to 99 months
Multiple Sclerosis Functional Composite (MSFC) Composite Score
기간: up to 99 months

The MSFC consists of the timed 25 foot walk test, the 9-hole peg test, and the Paced Auditory Serial Addition Test (PASAT) and a composite MSFC z-score will be evaluated.

up to 99 months
Timed 25 Foot Walk Test
기간: up to 99 months

Time taken to complete the timed 25 foot walk test, measured twice in units of seconds, will be averaged and evaluated.

up to 99 months
Nine-hole Peg Test
기간: up to 99 months

Time taken to complete the nine-hole peg test, measured twice for each hand (dominant and non-dominant) in units of seconds, will be averaged for each hand and evaluated.

up to 99 months
Paced Auditory Serial Addition Test (PASAT)
기간: up to 99 months

The paced auditory serial addition test that measures processing speed will be administered once; number and percent correct will be evaluated.

up to 99 months
Low contrast visual acuity
기간: up to 99 months

Low-contrast letter acuity (binocular, 2.5% contrast Sloan charts)

up to 99 months
Patient-reported incomplete relapse recovery
기간: up to 99 months

Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on patient self-report.

up to 99 months
Neurologic exam-based incomplete relapse recovery
기간: up to 99 months

Among participants identified to have a relapse, relapse recovery will be defined as complete or incomplete based on neurologic examination (those who have increased Functional System scores, corresponding to the relapse symptoms, of 1.0 point or greater for at least 6 months after the relapse onset, without subsequent accrual of worsening in that same Functional System (e.g. more indicative of progression), will be considered to have incomplete relapse recovery).

up to 99 months
Cognition using Symbol Digit Modality Test (SDMT)
기간: up to 99 months

The SDMT is commonly used in MS to assess processing speed and will be administered orally and used to evaluate changes in cognition throughout the study.

up to 99 months
Multiple Sclerosis Impact Scale (MSIS-29)
기간: up to 99 months

The MSIS-29 will be used to evaluate the impact of MS on the participants and will be administered as an electronic PRO.Multiple Sclerosis Impact Scale (MSIS-29) is an instrument used for measuring the physical (20 items) and psychological (nine items) impact of multiple sclerosis.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Anxiety Subscale
기간: up to 99 months

The Anxiety Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Depression Subscale
기간: up to 99 months

The Depression Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Fatigue Subscale
기간: up to 99 months

The Fatigue Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Upper Extremity Function
기간: up to 99 months

The Upper Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Lower Extremity Function
기간: up to 99 months

The Lower Extremity Function Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Cognitive Function
기간: up to 99 months

The Cognitive Function Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Positive Affect/Well-being
기간: up to 99 months

The Positive Affect/Well-being Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Sleep Disturbance
기간: up to 99 months

The Sleep Disturbance Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Ability to Participate in Social Roles and Activities
기간: up to 99 months

The Ability to Participate in Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Satisfaction with Social Roles and Activities
기간: up to 99 months

The Satisfaction with Social Roles and Activities Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Quality of Life in Neurological Disorders (Neuro-QoL): Stigma
기간: up to 99 months

The Stigma Subscale of Neuro-QoL will be administered as an electronic PRO.

up to 99 months
Employment status
기간: up to 99 months

The incidence of change in employment to "disabled" or "looking for work, unemployed," will be evaluated for all participants through an electronic PRO.

up to 99 months
Marital status
기간: up to 99 months

Incident divorce or separation, among those who previously were married or in a domestic partnership, will be evaluated for all participants through an electronic PRO.

up to 99 months
Serious Adverse Events (SAEs)
기간: up to 99 months

SAEs (clinically significant infections, malignancies, or the development of other serious comorbidities, as well as unplanned hospitalizations [for non-elective issues, excluding MS relapse] and death)

up to 99 months
Adverse event resulting in a decision to change disease-modifying therapy
기간: up to 99 months

Adverse events meaningful enough to lead to medication discontinuation

up to 99 months
Severe COVID-19 Infection
기간: up to 48 weeks from enrollment into COVID-19 related substudy

Severe COVID-19 infection will be defined as an outcome of "hospitalization or death" due to confirmed or suspected COVID-19 infection

up to 48 weeks from enrollment into COVID-19 related substudy

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Ellen M. Mowry, MD, MCR, Johns Hopkins University
  • 수석 연구원: Scott D. Newsome, DO, Johns Hopkins University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 5월 2일

기본 완료 (실제)

2026년 7월 31일

연구 완료 (실제)

2026년 8월 31일

연구 등록 날짜

최초 제출

2018년 2월 21일

QC 기준을 충족하는 최초 제출

2018년 4월 12일

처음 게시됨 (실제)

2018년 4월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • IRB00143534

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다